-
- Asami Yutaro
- Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University
-
- Yoshioka Kotaro
- Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University
-
- Nishina Kazutaka
- Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University
-
- Nagata Tetsuya
- Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University
-
- Yokota Takanori
- Department of Neurology and Neurological Science, Graduate School, Tokyo Medical and Dental University
書誌事項
- 公開日
- 2016
- 資源種別
- journal article
- DOI
-
- 10.5582/ddt.2016.01065
- 公開者
- 特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会
この論文をさがす
説明
<p>Therapeutic oligonucleotides are promising technologies. Nevertheless, improvement of their efficacy is an important issue. Introducing this drug delivery system (DDS) makes for a great enhancement for delivery of oligonucleotides to targeted tissue or cells. The strategy of DDS for therapeutic oligonucleotides is divided into four categories, A) single piece of oligonucleotide, B) oligonucleotide-ligand conjugate, C) oligonucleotide-polymer conjugate, and D) nanoparticle. In this review we will describe those basic concepts, especially for the technology of conjugating ligand. In addition, we developed a new technology, heteroduplex oligonucleotide (HDO), binding ligand-molecule to antisense oligonucleotide indirectly. We also outline α-tocopherol (a natural isomer of vitamin E) conjugated HDO.</p>
収録刊行物
-
- Drug Discoveries & Therapeutics
-
Drug Discoveries & Therapeutics 10 (5), 256-262, 2016
特定非営利活動法人 バイオ＆ソーシャル・サイエンス推進国際研究交流会
